Do analysts recommend TVGN or PHXM?

Tevogen Bio presently has a consensus price target of $100.00, indicating a potential upside of 1,633.10%. Given Tevogen Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Tevogen Bio is more favorable than PHAXIAM Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tevogen Bio 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings and valuation, TVGN or PHXM?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tevogen Bio N/A N/A -$26.27M -$4.61 N/A PHAXIAM Therapeutics N/A N/A -$240K N/A N/A

Is TVGN or PHXM more profitable?

Company Net Margins Return on Equity Return on Assets Tevogen Bio N/A N/A -472.77% PHAXIAM Therapeutics N/A N/A N/A

Do analysts rate PHXM or RNXT?

RenovoRx has a consensus target price of $8.50, indicating a potential upside of 823.81%. Given RenovoRx's stronger consensus rating and higher possible upside, analysts plainly believe RenovoRx is more favorable than PHAXIAM Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 RenovoRx 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75

Which has higher valuation & earnings, PHXM or RNXT?

PHAXIAM Therapeutics has higher earnings, but lower revenue than RenovoRx. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PHAXIAM Therapeutics N/A N/A -$240K N/A N/A RenovoRx $1.12M 37.01 -$11.17M -$0.33 N/A

Do analysts prefer ESLA or PHXM?

Estrella Immunopharma presently has a consensus target price of $8.00, indicating a potential upside of 714.25%. Given Estrella Immunopharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Estrella Immunopharma is more favorable than PHAXIAM Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Estrella Immunopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, ESLA or PHXM?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Estrella Immunopharma N/A N/A -$13.06M -$0.34 N/A PHAXIAM Therapeutics N/A N/A -$240K N/A N/A

Is ESLA or PHXM more profitable?

Company Net Margins Return on Equity Return on Assets Estrella Immunopharma N/A N/A -397.36% PHAXIAM Therapeutics N/A N/A N/A

Do analysts prefer BTAI or PHXM?

BioXcel Therapeutics presently has a consensus target price of $11.00, suggesting a potential upside of 697.10%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe BioXcel Therapeutics is more favorable than PHAXIAM Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, BTAI or PHXM?

PHAXIAM Therapeutics has lower revenue, but higher earnings than BioXcel Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioXcel Therapeutics $640K 66.59 -$69.90M -$5.75 N/A PHAXIAM Therapeutics N/A N/A -$240K N/A N/A

Is BTAI or PHXM more profitable?

PHAXIAM Therapeutics has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%. Company Net Margins Return on Equity Return on Assets BioXcel Therapeutics -11,078.53% N/A -201.53% PHAXIAM Therapeutics N/A N/A N/A

Do analysts recommend PHXM or MIRA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation and earnings, PHXM or MIRA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PHAXIAM Therapeutics N/A N/A -$240K N/A N/A MIRA Pharmaceuticals N/A N/A -$10.44M -$1.30 N/A

Is PHXM or MIRA more profitable?

PHAXIAM Therapeutics' return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets PHAXIAM Therapeutics N/A N/A N/A MIRA Pharmaceuticals N/A -140.82% -135.01%

PHAXIAM Therapeutics (PHXM) Competitors

$3.10 0.00 (0.00%)

As of 07/2/2026

Compare

PHXM vs. TVGN, RNXT, ESLA, BTAI, and MIRA

Should you buy PHAXIAM Therapeutics stock or one of its competitors? MarketBeat compares PHAXIAM Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PHAXIAM Therapeutics include Tevogen Bio (TVGN), RenovoRx (RNXT), Estrella Immunopharma (ESLA), BioXcel Therapeutics (BTAI), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical products" industry.

How does PHAXIAM Therapeutics compare to Tevogen Bio?

Tevogen Bio (NASDAQ:TVGN) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. 70.5% of Tevogen Bio shares are owned by insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Tevogen Bio has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, indicating that its stock price is 135% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	N/A	-472.77%
PHAXIAM Therapeutics	N/A	N/A	N/A

In the previous week, Tevogen Bio had 1 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 1 mentions for Tevogen Bio and 0 mentions for PHAXIAM Therapeutics. Tevogen Bio's average media sentiment score of 0.67 beat PHAXIAM Therapeutics' score of 0.00 indicating that Tevogen Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Tevogen Bio	Positive
PHAXIAM Therapeutics	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$26.27M	-$4.61	N/A
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A

Tevogen Bio presently has a consensus price target of $100.00, indicating a potential upside of 1,633.10%. Given Tevogen Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Tevogen Bio is more favorable than PHAXIAM Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Tevogen Bio beats PHAXIAM Therapeutics on 5 of the 9 factors compared between the two stocks.

How does PHAXIAM Therapeutics compare to RenovoRx?

PHAXIAM Therapeutics (NASDAQ:PHXM) and RenovoRx (NASDAQ:RNXT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment.

In the previous week, RenovoRx had 1 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 1 mentions for RenovoRx and 0 mentions for PHAXIAM Therapeutics. PHAXIAM Therapeutics' average media sentiment score of 0.00 equaled RenovoRx'saverage media sentiment score.

Company	Overall Sentiment
PHAXIAM Therapeutics	Neutral
RenovoRx	Neutral

0.4% of PHAXIAM Therapeutics shares are held by institutional investors. Comparatively, 3.1% of RenovoRx shares are held by institutional investors. 1.9% of PHAXIAM Therapeutics shares are held by insiders. Comparatively, 9.4% of RenovoRx shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

PHAXIAM Therapeutics has a beta of 2.35, meaning that its stock price is 135% more volatile than the broader market. Comparatively, RenovoRx has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market.

RenovoRx has a consensus target price of $8.50, indicating a potential upside of 823.81%. Given RenovoRx's stronger consensus rating and higher possible upside, analysts plainly believe RenovoRx is more favorable than PHAXIAM Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

PHAXIAM Therapeutics has higher earnings, but lower revenue than RenovoRx.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A
RenovoRx	$1.12M	37.01	-$11.17M	-$0.33	N/A

PHAXIAM Therapeutics has a net margin of 0.00% compared to RenovoRx's net margin of -823.98%. PHAXIAM Therapeutics' return on equity of 0.00% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PHAXIAM Therapeutics	N/A	N/A	N/A
RenovoRx	-823.98%	-135.03%	-101.92%

Summary

RenovoRx beats PHAXIAM Therapeutics on 8 of the 13 factors compared between the two stocks.

How does PHAXIAM Therapeutics compare to Estrella Immunopharma?

Estrella Immunopharma (NASDAQ:ESLA) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

0.3% of Estrella Immunopharma shares are owned by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. 5.8% of Estrella Immunopharma shares are owned by insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Estrella Immunopharma	N/A	N/A	-397.36%
PHAXIAM Therapeutics	N/A	N/A	N/A

Estrella Immunopharma has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, meaning that its share price is 135% more volatile than the broader market.

In the previous week, Estrella Immunopharma had 1 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 1 mentions for Estrella Immunopharma and 0 mentions for PHAXIAM Therapeutics. Estrella Immunopharma's average media sentiment score of 0.76 beat PHAXIAM Therapeutics' score of 0.00 indicating that Estrella Immunopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Estrella Immunopharma	Positive
PHAXIAM Therapeutics	Neutral

Estrella Immunopharma presently has a consensus target price of $8.00, indicating a potential upside of 714.25%. Given Estrella Immunopharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Estrella Immunopharma is more favorable than PHAXIAM Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A

Summary

Estrella Immunopharma beats PHAXIAM Therapeutics on 6 of the 10 factors compared between the two stocks.

How does PHAXIAM Therapeutics compare to BioXcel Therapeutics?

BioXcel Therapeutics (NASDAQ:BTAI) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

30.7% of BioXcel Therapeutics shares are owned by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. 3.7% of BioXcel Therapeutics shares are owned by company insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

BioXcel Therapeutics has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, meaning that its stock price is 135% more volatile than the broader market.

BioXcel Therapeutics presently has a consensus target price of $11.00, suggesting a potential upside of 697.10%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe BioXcel Therapeutics is more favorable than PHAXIAM Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, BioXcel Therapeutics' average media sentiment score of 0.00 equaled PHAXIAM Therapeutics'average media sentiment score.

Company	Overall Sentiment
BioXcel Therapeutics	Neutral
PHAXIAM Therapeutics	Neutral

PHAXIAM Therapeutics has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%.

Company	Net Margins	Return on Equity	Return on Assets
BioXcel Therapeutics	-11,078.53%	N/A	-201.53%
PHAXIAM Therapeutics	N/A	N/A	N/A

PHAXIAM Therapeutics has lower revenue, but higher earnings than BioXcel Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioXcel Therapeutics	$640K	66.59	-$69.90M	-$5.75	N/A
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A

Summary

BioXcel Therapeutics beats PHAXIAM Therapeutics on 6 of the 10 factors compared between the two stocks.

How does PHAXIAM Therapeutics compare to MIRA Pharmaceuticals?

PHAXIAM Therapeutics (NASDAQ:PHXM) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

In the previous week, PHAXIAM Therapeutics' average media sentiment score of 0.00 equaled MIRA Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
PHAXIAM Therapeutics	Neutral
MIRA Pharmaceuticals	Neutral

PHAXIAM Therapeutics' return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PHAXIAM Therapeutics	N/A	N/A	N/A
MIRA Pharmaceuticals	N/A	-140.82%	-135.01%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.30	N/A

0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. 1.9% of PHAXIAM Therapeutics shares are owned by insiders. Comparatively, 6.7% of MIRA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

PHAXIAM Therapeutics has a beta of 2.35, meaning that its share price is 135% more volatile than the broader market. Comparatively, MIRA Pharmaceuticals has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market.

Summary

PHAXIAM Therapeutics and MIRA Pharmaceuticals tied by winning 4 of the 8 factors compared between the two stocks.

Get PHAXIAM Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHXM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHXM vs. The Competition

Export

Metric	PHAXIAM Therapeutics	Biotechnology Industry	Medical Sector	NASDAQ Exchange
Market Cap	$10.58M	$431.50M	$7.16B	$12.48B
Dividend Yield	N/A	3.88%	2.66%	6.52%
P/E Ratio	N/A	3.09	28.02	24.70
Price / Sales	N/A	6,669.11	540.37	99.49
Price / Cash	N/A	13.13	49.26	57.09
Price / Book	0.39	88.67	10.96	6.46
Net Income	-$240K	-$96.07M	$3.57B	$337.01M
7 Day Performance	N/A	0.17%	2.12%	1.69%
1 Month Performance	N/A	2.10%	5.25%	3.81%
1 Year Performance	N/A	68.02%	33.29%	23.90%

PHAXIAM Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHXM PHAXIAM Therapeutics	N/A	$3.10 flat	N/A	N/A	$10.58M	N/A	N/A	49
TVGN Tevogen Bio	1.9459 of 5 stars	$9.51 -3.2%	$100.00 +951.5%	-90.7%	$41.12M	N/A	N/A	3	Positive News
RNXT RenovoRx	3.9913 of 5 stars	$0.91 +0.1%	$8.50 +833.3%	-31.8%	$41.05M	$1.12M	N/A	6	Gap Up
ESLA Estrella Immunopharma	2.2907 of 5 stars	$1.00 +7.1%	$8.00 +700.0%	+6.3%	$40.20M	N/A	N/A	N/A
BTAI BioXcel Therapeutics	1.6591 of 5 stars	$1.26 -3.1%	$11.00 +773.0%	-29.6%	$40.14M	$640K	N/A	90

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHXM) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PHAXIAM Therapeutics (PHXM) Competitors

PHXM vs. TVGN, RNXT, ESLA, BTAI, and MIRA

How does PHAXIAM Therapeutics compare to Tevogen Bio?

Summary

How does PHAXIAM Therapeutics compare to RenovoRx?

Summary

How does PHAXIAM Therapeutics compare to Estrella Immunopharma?

Summary

How does PHAXIAM Therapeutics compare to BioXcel Therapeutics?

Summary

How does PHAXIAM Therapeutics compare to MIRA Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHXM vs. The Competition

PHAXIAM Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PHAXIAM Therapeutics (PHXM) Competitors

PHXM vs. TVGN, RNXT, ESLA, BTAI, and MIRA

How does PHAXIAM Therapeutics compare to Tevogen Bio?

Do insiders & institutionals believe in TVGN or PHXM?

Which has more volatility and risk, TVGN or PHXM?

Is TVGN or PHXM more profitable?

Does the media favor TVGN or PHXM?

Which has stronger earnings and valuation, TVGN or PHXM?

Do analysts recommend TVGN or PHXM?

Summary

How does PHAXIAM Therapeutics compare to RenovoRx?

Does the media refer more to PHXM or RNXT?

Do institutionals and insiders believe in PHXM or RNXT?

Which has more risk and volatility, PHXM or RNXT?

Do analysts rate PHXM or RNXT?

Which has higher valuation & earnings, PHXM or RNXT?

Is PHXM or RNXT more profitable?

Summary

How does PHAXIAM Therapeutics compare to Estrella Immunopharma?

Do insiders & institutionals have more ownership in ESLA or PHXM?

Is ESLA or PHXM more profitable?

Which has more volatility and risk, ESLA or PHXM?

Does the media prefer ESLA or PHXM?

Do analysts prefer ESLA or PHXM?

Which has higher earnings and valuation, ESLA or PHXM?

Summary

How does PHAXIAM Therapeutics compare to BioXcel Therapeutics?

Do institutionals & insiders have more ownership in BTAI or PHXM?

Which has more volatility & risk, BTAI or PHXM?

Do analysts prefer BTAI or PHXM?

Does the media favor BTAI or PHXM?

Is BTAI or PHXM more profitable?

Which has stronger earnings & valuation, BTAI or PHXM?

Summary

How does PHAXIAM Therapeutics compare to MIRA Pharmaceuticals?

Does the media refer more to PHXM or MIRA?

Is PHXM or MIRA more profitable?

Which has preferable valuation and earnings, PHXM or MIRA?

Do institutionals & insiders believe in PHXM or MIRA?

Do analysts recommend PHXM or MIRA?

Which has more volatility and risk, PHXM or MIRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHXM vs. The Competition

PHAXIAM Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools